• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

Lilly’s Donanemab Hit with Surprise Delay, Set to Face FDA Adcomm

cafead

Administrator
Staff member
  • cafead   Mar 08, 2024 at 12:02: PM
via Eli Lilly on Friday announced that the FDA has decided to hold an advisory committee meeting to discuss its investigational Alzheimer’s disease antibody donanemab, pushing its target action date to beyond the first quarter of 2024.

article source
 

<